Important Overall Survival results in KEYNOTE-522.
Important advance for our patients with #early TNBC, but we are still waiting biomarker analyses for this trial... FDA Oncology OncoAlert Merck #bcsm #research

Today’s press release by Merck:
KEYNOTE-522 met its overall survival endpoint in high-risk early TNBC

Excellent news for our #breastcancer patients

OncoAlert

merck.com/news/merck-ann…

Thanks, ESMO - Eur. Oncology for the opportunity to discuss the landmark EV-302 paper - Patrizia Giannatempo
Istituto Tumori Evandro de Azambuja, MD, PhD Benjamin Besse
oncodaily.com/71358.html

#Cancer #ESMO #Cancer Research #OncoDaily #Oncology

#ESMOBreast24 : What do you find the most relevant #ScientificAdvancements in #OncologyResearch ? Share the newest findings that you consider having the potential to improve #CancerCare in #bcsm . #BreastCancer #ESMOAmbassadors

Only in few days and ESMO - Eur. Oncology will launch its first virtual journal club (Wednesday 22 May 2024, at 6:30pm CET). Hope to see you all there! Benjamin Besse @ValentinaGuarneri Elsevier Annals of Oncology #journalclub #research #education OncoAlert

What an epic #ESMOBreast24 ! Meeting friends and sharing the best knowledge #ESMOAmbassadors ESMO - Eur. Oncology Elisa Agostinetto ChiaraMolinelli Luca Arecco, MD Matteo Lambertini, MD PhD Diogo Martins Branco Daniel Eiger, MD 🇧🇷🇵🇱🇮🇱🇺🇦🇨🇭 Chiara Dauccia tsangtszying @Fatima Az-zahra Herdee Luna 🇵🇭

🔚 It's a wrap 💥
‼️ what a great #ESMOBreast24 👏

#ESMOBreast24 is getting to the end. Another fulfilling experience - very proud to have been awarded with a ESMO - Eur. Oncology Merit travel grant for our work🙏🏻
A big❤️to all colleagues and friends that made it possible and help improve #breastcancer care everyday
OncoAlert Institut Jules Bordet Instituut

19.7% discontinued ribociclib in Natalee but it appears not to impact in survival… but 35% discontinue ribo before completing 3 years. #ESMOBreast24
#ESMOAmbassadors
ESMO - Eur. Oncology

✔️we develop a #ML tool to predict #RSClin to refine DR risk and CT benefit for HR+HER2- #earlyBC
✔️our tool can accurately reproduce RSClin
✔️free web based link to access the tool ➡️ lnkd.in/dUk-EUrP
✔️this tool may support treatment decision for HR+ eBC
#ESMOBreast24

Safety of ART in #patients with BRCA1/2 mutation #breastcancer Matteo Lambertini, MD PhD #ESMOBreast24
#ESMOAmbassadors
ESMO - Eur. Oncology

Mini oral session at #ESMOBreast24 ESMO - Eur. Oncology #ESMOAmbassadors

#ESMOBreast24
#ESMOAmbassadors
ESMO - Eur. Oncology

#ESMOBreast24
#ESMOAmbassadors
ESMO - Eur. Oncology

Post-neoadjuvant therapy in patients with HR+/Her2 neg ESMO - Eur. Oncology #ESMOBreast24
#ESMOAmbassadors
Carmen Criscitiello

Do not miss the latest research findings in #BreastCancer brought to you by the #ESMOAmbassadors & become part of the conversation about the science presented at #ESMOBreast24 . #bcsm
👉 ow.ly/ILk450RE3ts

Join us at the next ESMO - Eur. Oncology Virtual Plenary session! - Giampaolo Bianchini
Elisa Agostinetto OncoAlert Evandro de Azambuja, MD, PhD

#BreastCancer #ClinicalTrial #ESMO #Metastatic #Cancer #OncoDaily #Oncology #PARP #Research

oncodaily.com/62751.html

Belgian Society of Medical Oncology newsletter is out! Kevin Punie Willem Lybaert @anneliesverbiest Barbara Hendrikx @christelfontaine @christinegennigens @cédricvanmarcke [email protected] FlorenceVanRyckeghem
canva.com/design/DAGCHZB…

The MONARCH 3 trial
Addition of abemaciclib to a nonsteroidal aromatase inhibitor (NSAI) as initial therapy for hormone receptor-positive, 🧬HER2-negative advanced #BreastCancer

✅ Significantly improved PFS and showed clinically meaningful improvement in OS

➡️ particularly

Evandro de Azambuja, MD, PhD discusses the results presented at ESMO - Eur. Oncology Virtual Plenary:
- improvement in PFS but also⬆️in toxicity;
- relatively small sample-size;
- Asian pts only (but no PARPi available in🇨🇳yet);
- results consistent according to HR status and prior platinum;
OncoAlert